• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤免疫逃逸机制:2000年最新进展

Escape mechanisms in tumor immunity: a year 2000 update.

作者信息

Pawelec G, Heinzel S, Kiessling R, Müller L, Ouyang Q, Zeuthen J

机构信息

Section for Transplantation Immunology, University of Tübingen, Germany.

出版信息

Crit Rev Oncog. 2000;11(2):97-133.

PMID:11005508
Abstract

The current consensus of opinion has it that most or possibly all tumors, spontaneous as well as induced, are immunogenic, expressing antigens in a form recognizable by the host immune system. Accordingly, in order to progress, tumors have to evolve strategies for evading immune responses. The purpose of this review is to consider the current status of knowledge concerning these different tumor escape strategies. It represents an update of an article originally published in this journal in 1997 (Pawelec, Zeuthen, and Kiessling, 1997). Therefore, it focuses mostly on publications that have appeared since then, illustrating the impressive accumulation of new data since that time and the importance currently attributed to studies of tumor escape from the immune response.

摘要

目前的共识观点认为,大多数甚至可能所有肿瘤,无论是自发的还是诱发的,都具有免疫原性,以宿主免疫系统可识别的形式表达抗原。因此,为了进展,肿瘤必须进化出逃避免疫反应的策略。本综述的目的是考虑关于这些不同肿瘤逃逸策略的当前知识状态。它是对1997年发表在本杂志上的一篇文章(Pawelec、Zeuthen和Kiessling,1997年)的更新。因此,它主要关注自那时以来出现的出版物,说明了自那时以来新数据的惊人积累以及目前对肿瘤免疫逃逸研究的重视程度。

相似文献

1
Escape mechanisms in tumor immunity: a year 2000 update.肿瘤免疫逃逸机制:2000年最新进展
Crit Rev Oncog. 2000;11(2):97-133.
2
Escape mechanisms in tumor immunity: an update.肿瘤免疫逃逸机制:最新进展
J Environ Pathol Toxicol Oncol. 2002;21(4):277-330.
3
Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?肿瘤免疫逃逸:癌症成功免疫治疗的最后一道障碍?
Cancer Immunol Immunother. 1999 Oct;48(7):343-5. doi: 10.1007/s002620050584.
4
Tumor-host immune interactions and dendritic cell dysfunction.肿瘤-宿主免疫相互作用与树突状细胞功能障碍。
Adv Cancer Res. 2004;92:13-27. doi: 10.1016/S0065-230X(04)92002-7.
5
Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?评论:免疫逃逸与肿瘤耐受:肿瘤如何逃避免疫监视?
Eur J Med Res. 2001 Aug 27;6(8):323-32.
6
[Immune response and cancer].[免疫反应与癌症]
Bull Cancer. 2008 Jan;95(1):57-67. doi: 10.1684/bdc.2008.0558.
7
Efficacy of clonal deletion vs. anergy of self-reactive CD4 T-cells for the prevention and reversal of autoimmune diabetes.克隆清除与自身反应性CD4 T细胞失能在预防和逆转自身免疫性糖尿病方面的疗效。
J Autoimmun. 2005 Aug;25(1):21-32. doi: 10.1016/j.jaut.2005.04.003.
8
Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.针对肿瘤免疫逃逸的治疗方法:迈向新一代抗癌疫苗的研发
Med Res Rev. 2008 May;28(3):413-44. doi: 10.1002/med.20110.
9
Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells.黑色素瘤细胞而非正常黑素细胞的凋亡阶段,对髓样树突状细胞的成熟有不同影响。
Cancer Res. 2001 Nov 15;61(22):8218-26.
10
Escape from host-antitumor immunity.逃避宿主抗肿瘤免疫。
Crit Rev Oncog. 1997;8(2-3):111-41. doi: 10.1615/critrevoncog.v8.i2-3.10.

引用本文的文献

1
In vivo and in vitro antitumor effects of platycodin d, a saponin purified from platycodi radix on the h520 lung cancer cell.从桔梗中提取的皂苷桔梗皂苷 D 在体内和体外对 H520 肺癌细胞的抗肿瘤作用。
Evid Based Complement Alternat Med. 2014;2014:478653. doi: 10.1155/2014/478653. Epub 2014 Nov 13.
2
Cancer treatment: the combination of vaccination with other therapies.癌症治疗:疫苗接种与其他疗法的联合应用。
Cancer Immunol Immunother. 2008 Nov;57(11):1735-43. doi: 10.1007/s00262-008-0480-y. Epub 2008 Feb 20.
3
Mutation in the immunodominant epitope of the HPV16 E7 oncoprotein as a mechanism of tumor escape.
人乳头瘤病毒16型E7癌蛋白免疫显性表位的突变作为肿瘤逃逸机制
Cancer Immunol Immunother. 2008 Jun;57(6):823-31. doi: 10.1007/s00262-007-0418-9. Epub 2007 Oct 26.
4
Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes.原发性黑色素瘤病灶与相应的无肿瘤前哨淋巴结中相同T细胞受体的鉴定。
Cancer Immunol Immunother. 2006 May;55(5):495-502. doi: 10.1007/s00262-005-0023-8. Epub 2005 Jul 7.
5
CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression.与CD3-ζ链表达相比,乳腺癌患者前哨淋巴结活检中CD28的表达情况。
J Transl Med. 2004 Dec 21;2(1):45. doi: 10.1186/1479-5876-2-45.
6
Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?有效的癌症免疫疗法:是一个克服免疫抑制和免疫逃逸的问题吗?
Cancer Immunol Immunother. 2004 Oct;53(10):879-92. doi: 10.1007/s00262-004-0577-x. Epub 2004 Jul 28.
7
NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.在依赖自然杀伤细胞的免疫治疗后复发时,NXS2小鼠神经母细胞瘤表达的主要组织相容性复合体I类抗原水平升高。
Cancer Immunol Immunother. 2004 Jan;53(1):41-52. doi: 10.1007/s00262-003-0435-2. Epub 2003 Sep 18.
8
Assumptions of the tumor 'escape' hypothesis.肿瘤“逃逸”假说的假设。
Semin Cancer Biol. 2002 Feb;12(1):81-6. doi: 10.1006/scbi.2001.0399.
9
Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors.通过丝氨酸蛋白酶抑制剂PI-9/SPI-6的过表达来阻断颗粒酶B/穿孔素途径,构成了肿瘤免疫逃逸的一种机制。
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11515-20. doi: 10.1073/pnas.201398198. Epub 2001 Sep 18.